Old Web
English
Sign In
Acemap
>
authorDetail
>
M. Ubukata
M. Ubukata
Taisho Pharmaceutical Co.
Internal medicine
Endocrinology
SGLT2 Inhibitor
Placebo
Crossover study
2
Papers
53
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet.
2016
Diabetes, Obesity and Metabolism
Rimei Nishimura
Hirohisa Omiya
K. Sugio
M. Ubukata
Soichi Sakai
Yoshishige Samukawa
Show All
Source
Cite
Save
Citations (18)
Effects of luseogliflozin, a sodium–glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study
2015
Diabetes, Obesity and Metabolism
Rimei Nishimura
T. Osonoi
S. Kanada
H. Jinnouchi
K. Sugio
Hirohisa Omiya
M. Ubukata
Soichi Sakai
Yoshishige Samukawa
Show All
Source
Cite
Save
Citations (35)
1